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Abstract
Background: There is a substantial clinical overlap between chronic renal failure (CRF) and
hypothyroidism, suggesting the presence of hypothyroidism in uremic patients. Although CRF
patients have low T3 and T4 levels with normal thyroid-stimulating hormone (TSH), they show a
higher prevalence of goiter and evidence for blunted tissue responsiveness to T3 action. However,
there are no studies examining whether thyroid hormone receptors (TRs) play a role in thyroid
hormone dysfunction in CRF patients. To evaluate the effects of an uremic environment on TR
function, we investigated the effect of uremic plasma on TRβ 1 binding to DNA as heterodimers
with the retinoid X receptor alpha (RXRα ) and on T3-dependent transcriptional activity.
Results:  We demonstrated that uremic plasma collected prior to hemodialysis (Pre-HD)
significantly reduced TRβ 1-RXRα  binding to DNA. Such inhibition was also observed with a vitamin
D receptor (VDR) but not with a peroxisome proliferator-activated receptor gamma (PPARγ ). A
cell-based assay confirmed this effect where uremic pre-HD ultrafiltrate inhibited the
transcriptional activation induced by T3 in U937 cells. In both cases, the inhibitory effects were
reversed when the uremic plasma and the uremic ultrafiltrate were collected and used after
hemodialysis (Post-HD).
Conclusion: These results suggest that dialyzable toxins in uremic plasma selectively block the
binding of TRβ 1-RXRα  to DNA and impair T3 transcriptional activity. These findings may explain
some features of hypothyroidism and thyroid hormone resistance observed in CRF patients.
Background
Chronic renal failure (CRF) is associated with distur-
bances in the internal milieu, with repercussions on the
immune, hematopoietic, gastrointestinal and endocrine
systems and organs [1-4]. Patients with advanced CRF dis-
play a variety of hormonal abnormalities including
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perturbations of the hypothalamic-pituitary-thyroid hor-
mone endocrine axis. The peripheral thyroid hormone
metabolism is also altered in patients with CRF [5-9].
In uremia various thyroid hormone physiological charac-
teristics are altered. Total and free tyroxine (T4) and 3,5,3'-
triiodothyronine (T3) levels in the serum are frequently
reduced in patients with CRF [10,11]. Reduced T3 levels
might be explained by decreased peripheral tissue conver-
sion of T4 to T3 [12]. Most CRF patients, however, are con-
sidered to be euthyroid as evidenced by normal thyroid-
stimulating hormone (TSH) levels [11,13]. In addition,
the prevalence of thyroid diseases, including goiter and
hypothyroidism, are also higher in CRF patients than in
the general population [10].
Thyroid hormones control numerous aspects of mamma-
lian development and metabolism, of which most of
these actions are mediated by specific thyroid hormone
receptors (TRs). An important metabolic activity of thy-
roid hormones is to increase oxygen consumption of tar-
get tissues [14,15]. In fact, in experimental renal failure
and in uremic patients the expected increase in basal oxy-
gen consumption following the administration of T3 is
not observed, suggesting that CRF is associated with resist-
ance to thyroid hormone action [16-18]. However, it is
currently not known whether thyroid hormone receptors
play a role in the thyroid dysfunction observed in uremic
patients.
TRs are ligand-regulated transcription factors of the
nuclear receptor superfamily which includes steroid hor-
mones and vitamin D receptors and also PPARγ
[15,19,20]. TRs modulate gene expression by binding spe-
cific DNA sequences, known as thyroid response elements
(TREs), found in the promoters of TR-regulated genes.
TREs are composed of repeats of the consensus half-site
AGGTCA in a variety of different orientations, including
direct repeats spaced by four nucleotides (DR-4), inverted
palindromes (F2) and palindromes [21,22]. In the pres-
ence of T3, TRs preferentially form heterodimers with the
retinoid X receptors (RXRs) although unliganded TR
binds to DNA as either homodimers or monomers
[20,23].
In recent years, it has become apparent that uremic toxins
can impair the function of some nuclear receptors, such as
the vitamin D receptor (VDR). Previous studies suggest
that uremic toxins inhibit the binding of VDR to DNA and
can contribute to the vitamin D resistance observed in
CRF patients [24-28]. It is, therefore, conceivable that ure-
mia also induces modifications in thyroid hormone
receptors and consequently plays a role in the thyroid hor-
mone dysfunction observed in uremic patients.
We investigated the effects of uremia on TRβ 1 function by
studying the ability of TRs to bind to DNA sequences in
the presence or absence of uremic plasma collected from
CRF patients. Our results showed that uremic plasma sig-
nificantly reduced the binding of TR heterodimers (TRβ 1-
RXRα ), but not of homodimers (TRβ 1-TRβ 1) to DR-4.
Furthermore, uremic plasma also inhibited the binding of
a VDR heterodimer (VDR-RXR) to DR-3, while the bind-
ing of PPARγ  to DR-1 remained unaltered. Moreover,
hemodialysis (HD) diminished the inhibitory effect of
CRF patients' plasma on the binding of both TR and VDR
heterodimers to DNA. When human promonocyte cells
were incubated with ultrafiltrate collected Pre-HD the
transcriptional activation induced by T3 was inhibited.
This inhibition was lost when the cells were treated with
ultrafiltrate collected after-HD. Thus, we suggest that dia-
lyzable uremic toxins selectively block the binding of
TRβ 1-RXRα  and VDR-RXR heterodimers to DNA and
reduce the transcriptional activities regulated by these
receptors. These results indicate that the thyroid hormone
dysfunction observed in uremia may be partially
explained by T3  resistance induced by impaired TRβ 1
function.
Results
Uremic plasma inhibits the binding of hTRβ 1-hRXRα  on 
DR-4
To study the effects of uremic plasma on the ability of
TRβ 1 to bind to a specific TRE we analyzed the binding of
hRXRα -hTRβ 1 heterodimers to DR-4. In this assay, the
protein-DNA complex was visualized by labeling the
TRβ 1 with 35S. In the presence of T3, the addition of
increasing amounts (Figure 1; lanes 2–4) of plasma from
normal individuals improved the binding of hRXRα -
hTRβ 1 to DNA. Conversely, TR incubation with uremic
plasma (lanes 5–7) collected prior to hemodialysis signif-
icantly reduced the binding of heterodimers (RXR-TR) to
DR-4. Band densitometry analysis of 5 independent
experiments showed that uremic plasma reduced hRXRα -
hTRβ 1-DR-4 complex formation by 77 ± 15%, compared
to plasma from normal subject (not shown). Similar
results were observed for the thyroid response element F2
(inverted palindrome) in which uremic plasma also
inhibited the RXR-TR binding to DNA (not shown). Pre-
treatment of hTRβ 1 with T3 failed to improve the ability of
the dimer hRXRα -hTRβ 1 to bind to DNA.
We used uremic plasma from four different patients to
determine whether the observed inhibition of RXRα -TRβ 1
binding to DNA (DR-4) was patient specific. Uremic
plasma samples from all four patients inhibited RXRα -
TRβ 1 binding to DR-4 to various degrees (not shown).
However, we could not detect any correlation between TR
binding impairment and abnormalities in plasma levels
of urea, creatinine or thyroid hormone.Nuclear Receptor 2005, 3:1 http://www.nuclear-receptor.com/content/3/1/1
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To exclude the possibility that the inhibition of hRXRα -
hTRβ 1 binding to DNA induced by uremic plasma could
be due to proteolytic degradation of TRβ 1, we incubated
35S-labeled TRβ 1, at the same conditions as in the gel-shift
experiments, with normal or uremic plasma at 4°C, for
thirty minutes. 35S-labeled TRβ 1 samples were then ana-
lyzed by SDS-PAGE. As expected, the major translation
product of TRβ 1 was 53 kD and incubation of theses
products with normal or uremic plasma did not modify
the translated [35S]TRβ 1 (Figure 2). These results indi-
cated an absence of uremic proteolytic activity that might
be involved in the decrease of TR-RXR complex formation
on DNA.
Hemodialysis improves hTRβ 1-hRXRα  binding to DR-4
It is yet unknown why uremic plasma diminished TRβ 1-
RXRα  binding to DNA, when compared to non-uremic
plasma. The observed effect could be ascribed either to a
lack of some factor(s) typically present in normal plasma
or to the presence of some inhibitory products present in
uremic plasma. To test the second hypothesis, we ana-
lyzed the influence of uremic plasma, collected before and
after hemodialysis, on TRβ 1-RXRα -DR-4 complex forma-
tion using gel-shift assays. In these experiments, [35S]
TRβ 1 was incubated with normal or uremic plasma, col-
lected before (pre-HD) or 4 h after hemodialysis (post-
HD). As shown in Figure 3, uremic plasma collected
before HD (lanes 5–7) decreased the binding of hTRβ 1-
hRXRα  to DNA (DR-4), relative to normal plasma (lanes
2–4). However, when these receptors were pre-incubated
with uremic plasma collected from the same patient after
hemodialysis (lane 8–10), an important improvement of
hTRβ 1-hRXRα  binding to DR-4 was observed. Although
hemodialysis improved complex formation, it did not
completely recover the inhibition caused by uremic
plasma. Densitometry analysis demonstrated that
Uremic plasma reduces hTRβ 1-hRXRα  complex formation on DR-4 Figure 1
Uremic plasma reduces hTRβ 1-hRXRα  complex formation on DR-4. Gel Shift experiments were performed using in 
vitro translated [35S] hTRβ 1, cold hRXRα  and DR-4. [35S] hTRβ 1 was treated with T3 10-7M for 30 min at 4°C and then incu-
bated without (Control – lane 1) or with increasing volumes (0.5, 1.0, 2.0 µL) of normal (lanes 2–4) or uremic (lanes 5–7) 
plasma for 30 min at 4°C. Cold DR-4 type TRE (5'- AGCT TC AGGTCA CAGG AGGTCA GAG - 3'), cold hRXRα , and 
nonspecific DNA poly (dIdC) were subsequently added and incubated for 20 min.Nuclear Receptor 2005, 3:1 http://www.nuclear-receptor.com/content/3/1/1
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Lack of proteolytic activity of uremic plasma on TRβ 1 Figure 2
Lack of proteolytic activity of uremic plasma on TRβ 1. Recombinant [35S]TRβ 1 was produced by translation in reticu-
locyte lysate and then incubated for 30 min at 4°C without (Control – lane 1) or with increasing volumes (0.5, 1.0, 2.0 µL) of 
normal (lanes 2–4) or uremic (lanes 5–7) plasma. Products were analyzed by SDS-PAGE and autoradiography.
Hemodialysis reduces the inhibitory effect of uremic plasma on hTRβ 1-hRXRα  binding to DR-4 Figure 3
Hemodialysis reduces the inhibitory effect of uremic plasma on hTRβ 1-hRXRα  binding to DR-4. [35S] hTRβ 1 was 
pre-incubated without (Control – lane 1) or with increasing volumes (0.5, 1.0, 2.0 µL) of normal (lane 2–4) or uremic plasma 
(patient 1) collected before (pre-HD – lanes 5–7) or after hemodialysis (pos-HD – lanes 8–10) for 30 min at 4°C. Cold DR-4 
type TRE, cold hRXRα , and nonspecific DNA poly (dIdC) were subsequently added and incubated for 20 min.Nuclear Receptor 2005, 3:1 http://www.nuclear-receptor.com/content/3/1/1
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hemodialysis increased by 50% the hTRβ 1-hRXRα  het-
erodimer binding to DNA when compared to pre-HD ure-
mic plasma (not shown).
Hemodialysis reduces the inhibitory effect of uremic 
plasma upon hVDR-RXRα  binding to DNA
In view that HD improved the binding of hTRβ 1-hRXRα
to DR-4 response element, and that previous studies
showed that uremic solutions inhibited hVDR-RXRα
binding to DR-3-response element (VDRE) [26,27,29] we
decided to determine whether uremic plasma collected
before and after hemodialysis has the same effect on
hVDR-RXRα  binding to DR-3.
Accordingly, a similar experiment was carried out with
hVDR treated with 1,25 (OH)2  D3  vitamin (VD3).
[35S]hVDR was incubated with non-uremic plasma, ure-
mic plasma collected before and after hemodialysis. As
shown in Figure 4, in comparison to control (lane1), the
incubation of VDR with plasma from normal individuals
increased [35S]hVDR-RXRα  binding to DR-3 (lanes 2–4).
In contrast, when [35S]VDR was incubated with uremic
plasma collected before HD, we observed a significant
reduction of hVDR-hRXRα  binding to DR-3 (lane 5–7).
On the other hand, when compared to pre-HD uremic
plasma pre-incubation with uremic plasma collected after
hemodialysis (lanes 8–10) improved hVDR-hRXRα  bind-
ing to DR-3. Taken together, these results suggest that dia-
lyzable toxins were responsible for the reduced binding of
hTRβ 1-hRXRα  and VDR-RXRα  to DNA.
Uremic plasma does not inhibit the binding of the hPPARγ -
hRXR heterodimer to DR-1
Next we decided to evaluate whether uremic plasma
impairs DNA binding of other members of the nuclear
receptor superfamily. We performed gel shift assays using
the nuclear fatty acid receptor PPARγ  and its response ele-
ment, DR-1. Members of the PPAR family have been
shown to play an important role in obesity and the plu-
rimetabolic syndrome [30] and insulin resistance has also
been described in uremic patients [31]. In contrast to what
was observed with TRβ 1 and VDR, Figure 5 shows that the
incubation of [S35] hPPARγ  with uremic plasma failed to
reduce the binding of PPARγ -hRXRα  to DR-1 (lanes 2–4
compared to lanes 5–7). Such finding suggests that the
inhibitory effect of uremic plasma does not extend to all
members of nuclear receptor superfamily.
Uremic plasma inhibits VDR-RXRα -DR-3 complex formation and hemodialysis reduces this effect Figure 4
Uremic plasma inhibits VDR-RXRα -DR-3 complex formation and hemodialysis reduces this effect. Gel Shift 
experiments were performed using in vitro translated [35S] hVDR and cold hRXRα . [35S] hVDR was incubated with VD3 vita-
min for 30 min at 4°C and then without (Control – lane 1) or with increasing volumes (0.5, 1.0, 2.0 µL) of normal (lanes 2–4) 
or uremic plasma, collected before (pre-HD – lanes 5–7) and after hemodialysis (pos-HD – lanes 8–10) from patient 1, for 30 
min. Cold DR-3 type VDRE (5'- AGCT TC AGGTCA AGG AGGTCA GAG - 3'), cold hRXRα , and nonspecific DNA poly 
(dIdC) were subsequently added and incubated for 20 min.Nuclear Receptor 2005, 3:1 http://www.nuclear-receptor.com/content/3/1/1
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The inhibitory activity of uremic plasma is not thermo-
labile
Our findings demonstrated that hemodialysis partially
corrected the inhibition of hTRβ 1-hRXRα  binding to DR-
4 caused by uremic plasma. We therefore hypothesized
that dialyzable toxins may cause the inhibitory effect of
uremic plasma on protein-DNA complex formation. To
gather more information on the nature of these toxins we
heated normal and uremic plasma for 5 minutes at 100°C
to test if the inhibitory factor was thermo-labile. We sub-
sequently performed gel shift assays. To control for our
experimental setup we used in these experiments [32P]
labeled DR-4 with unlabelled TRβ 1-RXRα  (Figure 6). Fur-
thermore, in order to avoid any effect from plasmatic
phosphatases on [32P] DNA, we also incubated the nor-
mal and uremic plasmas with a phosphatase inhibitor
cocktail (lane 6).
Heating the plasma from normal individual did not affect
the binding of the hTRβ 1-hRXRα  heterodimer to [32P]
DR-4 (lane 1 compared to lane 2). As shown in prior
experiments, uremic plasma significantly diminished the
hTRβ 1-hRXRα  – [32P] DR-4 complex formation (lane 4).
However, heating the uremic plasma did improve the
binding of the hTRβ 1-hRXRα  heterodimer to [32P] DR-4
(lane 5). In addition, the effects of uremic plasma per-
sisted in the presence of phosphatase inhibitors (lane 6).
Uremic Ultrafiltrate Impairs T3 Transcriptional Activation
Lastly we examined if the in vitro inhibitory effect of ure-
mic plasma on TR binding to DNA could affect the func-
tions of TR as a transcription regulator in a cell based assay
(Figure 7). We transfected U937 cells with cDNA encod-
ing the human TRβ 1 and a reporter gene with a DR-4
response element upstream of the firefly luciferase coding
sequence. We used RPMI-1640 medium treated with
ultrafiltrate (UF) solution 10-fold concentrated from nor-
mal or uremic patients collected before or after hemodial-
ysis. As shown in Figure 7, in the absence of any UF
(Control), T3 activated transcription by 5.7 ± 1.2 fold.
When the cells were treated with UF from normal individ-
uals, we did not observe significant changes in the tran-
scription activation of the luciferase reporter (4.7 ± 0.74
fold; ns). Interestingly, when compared to the UF from
normal individuals, UF collected Pre-HD from uremic
patients reduced T3-dependent transcriptional activation
by 66% (1.6 ± 0.35, p < 0.05). On the other hand, U937
cells treated with UF collected Post-HD had no significant
effect on T3-dependent transcription activation (4.8 ±
1.47 fold; ns). These results suggest that uremic toxins
impair T3  induced transcriptional activation and that
hemodialysis reduces their inhibitory effect.
Discussion
Uremia is a systemic chemical toxemia with repercussions
on different organs and systems. Chronic renal failure
patients demonstrate several endocrine dysfunctions,
such as disturbance of thyroid hormone metabolism and
Uremic plasma does not decrease PPARγ -RXRα -DR-1 complex formation Figure 5
Uremic plasma does not decrease PPARγ -RXRα -DR-1 complex formation. Gel Shift experiments were performed 
using in vitro translated [35S] PPARγ  and cold hRXRα . [35S] PPARγ  was incubated without (Control – lane 1) or with increasing 
volumes (0.5, 1.0, 2.0 µL) of normal (lanes 2–4) or uremic (lanes 5–7) plasma for 30 minutes. Cold DR-1 type TRE (5'- AGCT 
TC AGGTCA G AGGTCA GAG - 3'), cold hRXRα , and nonspecific DNA poly (dIdC) were subsequently added and the 
reaction was incubated for 20 min.Nuclear Receptor 2005, 3:1 http://www.nuclear-receptor.com/content/3/1/1
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are different from patients with the euthyroid sick
syndrome. In the later, the conversion of T4  to T3  is
reduced, but the generation of reverse T3 (rT3) from T4 is
increased. In uremic patients, rT3 is typically normal [32-
34]. In addition, Lim et al. showed thyroid hormone
resistance in hemodialysis patients with significantly
Heating the uremic plasma does not diminish the inhibition of hTRβ 1-hRXRα  binding to DR-4 Figure 6
Heating the uremic plasma does not diminish the inhibition of hTRβ 1-hRXRα  binding to DR-4. Gel Shift experi-
ments were performed using in vitro translated cold hTRβ 1, cold hRXRα  and [32P]DR-4. Cold hTRβ 1 was pre-incubated with 
normal or uremic plasma, heated or not, and in the presence or absence of phosphatase inhibitor for 30 min at 4°C. [32P] DR-
4 type TRE, cold hRXRα , and nonspecific DNA poly (dIdC) were subsequently added and the reaction was incubated for 20 
min.Nuclear Receptor 2005, 3:1 http://www.nuclear-receptor.com/content/3/1/1
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reduced peripheral tissue sensitivity to thyroid hormone
[17]. Recent data from our laboratory indicate that in
order to maintain the euthyroid state showed that uremia
increases T3 influx across erythrocyte's membrane [35].
Taken together, these findings suggest that CRF affects thy-
roid function in multiple ways. The molecular mecha-
nisms involved and the role of thyroid hormone receptor
in this dysfunction, however, are not fully understood.
In the present study we observed that uremic plasma
impaired the ability of TRβ 1 and VDR heterodimers
(TRβ 1-RXRα  and VDR-RXRα ) to bind to DNA (DR-4 and
DR-3 respectively), whereas that the ability of PPARγ -
RXRα  to bind to DNA (DR-1) was not altered. Interest-
ingly, there was no correlation between the inhibitory
activity and the plasma levels of urea, creatinine, parathy-
roid and thyroid hormone of the patients enrolled in this
study. However, the small number of patients precludes
any definitive conclusions.
To investigate whether these findings were secondary to
the presence of uremic dialyzable toxins, we compared the
effect of uremic plasma collected before and after hemo-
dialysis, on TRβ 1-RXRα  or VDR-RXRα  binding to DNA.
Our results showed that the inhibitory effect of uremic
plasma was significantly reduced by hemodialysis, sug-
gesting that dialyzable toxins were in fact involved. We
did not identify which toxin is responsible for this effect,
but our results suggest the presence of thermo-resistant
molecule(s). Further analyses of these dialyzable toxins
are currently being conducted to identify and characterize
the molecules responsible for this inhibitory effect.
The mechanisms responsible for our findings are not
clear. In uremic syndrome the reduced clearance of many
toxins plays a key role in this pathogenesis. Although VDR
degradation has been suggested in renal failure [36], the
uremic inhibition of TRβ 1-RXRα  binding to DNA could
not be explained by proteolytic activity of uremic plasma
since our SDS-PAGE did not show any uremic plasma-
dependent degradation of TRβ 1.
Our results are in agreement with other studies, which
have shown that uremic toxins are involved in VD3 resist-
ance observed in patients with chronic renal failure [37].
Uremic ultrafiltrates derived from hemo or peritoneal dia-
lyzed patients have been shown to inhibit the interaction
of VDR with DNA [27,28]. Further studies showed that
the VDR complex formation on different types of VDREs
can be reduced by uremic solutions collected from
patients after hemo or peritoneal dialysis [28]. Our results
allow us to speculate on the possibility of a common
inhibitory mechanism involving the same uremic toxin(s)
inhibiting both TR-RXR-DR-4 and VDR-RXR-DR-3 com-
plex formation.
To evaluate whether uremic toxins also affect other mem-
bers of the nuclear receptor family, we studied the effect of
uremic plasma on PPARγ -RXRα  binding to DR-1. Con-
trary to what we observed with TRβ 1 and VDR, pre-incu-
bation of PPARγ  with uremic plasma did not influence
PPARγ -RXRα  binding to DNA. This result suggests that the
inhibition of protein-DNA complex caused by uremic
plasma occurs only with some nuclear receptors. Taken
together, our results indicate that uremic toxins exert their
inhibitory effect by acting specifically on TRβ 1 and VDR
heterodimers.
The molecular mechanism involved in this phenomenon
is not clear. The fact that PPARγ -RXRα  heterodimer was
not affected by uremic plasma suggests that these toxins
do not interact directly with RXRα . Another possible
model to explain the effects of the toxins from uremic
plasma on the binding of TR to DNA would be a direct
action on DNA that would block its interaction with TRβ 1
and VDR heterodimers. However, even though we used
the DR-1 in PPARγ  assay, in contrast to DR-4 (TRE) and
Uremic toxin (s) impair (s) T3-dependent transcriptional acti- vation in U937 cells Figure 7
Uremic toxin (s) impair (s) T3-dependent transcrip-
tional activation in U937 cells. A reporter construct con-
sisting of two copies of a direct repeat thyroid response 
element (DR-4) 5'AGGTCAcaggAGGTCA 3' cloned 
upstream from the minimum thymidine kinase (TK) pro-
moter, linked to the luciferase gene was examined in U937 
cells. After electroporation, cells were transferred to fresh 
RPMI-1640 medium without (Control) or with normal or 
uremic ultrafiltrate solution, collected before (Pre-HD) or 
after hemodialysis (Post-HD). The cells were then plated in 
12-well dish and treated with T3 10-7M. After 24 h, cells were 
assayed for luciferase and β -galactosidase activities. * p < 
0.05 versus control and normal ultrafiltrate.Nuclear Receptor 2005, 3:1 http://www.nuclear-receptor.com/content/3/1/1
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DR-3 (VDRE), this hypothesis is not strongly supported
by the results from this study, as PPARγ -RXRα  heterodim-
ers bind normally to DNA in the presence of uremic
plasma. Another alternative that can not be excluded is an
inhibitory effect of the uremic toxin on the surface of TR
and VDR DNA binding domain (DBD), disrupting its
ability to binding to DNA. Patel et al. attributed to the for-
mation of Schiff bases between "reactive aldehydes" and
lysine residues of the DBD of the VDR to explain the
inhibitory effect of the uremic ultrafiltrate on the binding
of VDR to DNA [26]. Nevertheless, in another study, point
mutagenesis of different lysine residues in the DBD could
not confirm this idea [28]. In addition, we should con-
sider that the uremic toxins can interact with TR and VDR,
causing structural conformational changes on these recep-
tors, consequently, impairing heterodimers formation.
We attempted to demonstrate the physiological relevance
of these results by examining the effect of uremic toxins
on T3 transcriptional activation. Our results showed that
uremic ultrafiltrate collected before hemodialysis inhib-
ited T3-induced transcriptional activation, confirming the
in vitro findings. Conversely, in the presence of ultrafiltrate
collected after hemodialysis, the transcriptional activation
induced by T3 was similar to the control group treated
with ultrafiltrate collected from normal individuals.
Therefore, we hypothesize that dialyzable toxins are
responsible for the resistance to T3 action documented in
CRF patients.
In summary, uremic toxins circulating in the plasma of
CRF patients selectively reduced the binding of TRβ 1-
RXRα  to DNA and impaired the TRβ 1 transcriptional acti-
vation mediated by T3. Moreover, hemodialysis partially
corrected this inhibitory effect, suggesting the presence of
a dialyzable toxin. Since TRβ 1 functions as a heterodimer
with RXRα , these findings might explain some features of
hypothyroidism and thyroid hormone resistance com-
monly found in CRF patients. Future studies are necessary
to identify the toxins and further characterize the mecha-
nisms involved in resistance to T3 action in CRF patients.
Materials and methods
Patients and Clinical Procedures
Four patients from the chronic dialysis program of
Soclimed Dialysis Clinic were enrolled in our study. All
patients were men whose age ranged from 19 to 43 years
with the mean age being 34 years. They appeared well
nourished and clinically and laboratorial euthyroid; none
had a history of thyroid disease, thyroid hormone
therapy, treatment with amiodarone or clinically detecta-
ble goiter. Etiology of their chronic renal failure was as fol-
lows: chronic glomerulonephritis (2); hypertension (1);
reflux nephropathy (1). Mean plasma urea level was 178
± 44.8 mg/dL (120 to 233 mg/dL), while that of creatinine
was 12.6 ± 2.7 mg/dL (9.9 to 16.3 mg/dL). Patients were
on hemodialysis 3 times a week, during 4 hours using a
1.8 m2 Fresenius® Polysulfone filter. Normal control sub-
jects consisted of three healthy men, age ranging from 23
to 41 years, with the mean age of 32 years. The experimen-
tal protocol was approved by the Human Rights in
Research Committee of the University of Brasilia and all
patients and normal individuals gave their informed
consent.
For the in vitro DNA binding assay, uremic plasma was
collected immediately before and after 4 h of hemodialy-
sis, aliquoted into 20 µL samples and stocked at -20°C.
Uremic ultrafiltrate (UF) was also collected pre and post 4
h hemodialysis. Lyophilisation was used to concentrate
ultrafiltrate samples. The lyophilisates were re-suspended
in bidistillated water to a 10-fold concentrated solution,
as effects of the UF were not detectable at lower concentra-
tions (1 fold, 2.5 fold, 5 fold concentrated; not shown).
Samples were subsequently desalted by filtration using
Centricon 3 filters. Following centrifugation, the pellet
was re-suspended in RPMI-1640 medium, (10% newborn
bovine serum; 2 mM glutamine; 50 units/mL penicillin;
50 µg/mL streptomycin) and pH corrected to 7. Normal
UF was collected from control plasma of normal individ-
uals. The treatment solution was prepared in the same
manner as the uremic solution. All experiments were per-
formed with the uremic sample from the same patient
that showed the strongest inhibitory effect.
Gel shift binding assay
Gel shift assays were used to evaluate the binding of 35S-
labeled TR synthesized in reticulocyte lysate on 600
fmoles of unlabeled DR-4 (5'-AGCT TC AGGTCA CAGG
AGGTCA GAG -3') and inverted palindrome – F2 (5'-TTC
TGACCC CATTGG AGGTCA GAG -3'); 35S-labeled VDRs
to unlabeled DR-3 5'- AGCT TC AGGTCA AGG AGGTCA
GAG - 3') and 35S-labeled PPARγ  to unlabeled DR-1 (5'-
AGCT TC AGGTCA G AGGTCA GAG - 3'). Sensitivity and
specificity of this assay have been previously characterized
[23]. Briefly, the labeled protein will migrate in the non-
denaturating polyacrylamide gel only when bound to
DNA. Additionally, gel shift were also performed using
unlabeled synthesized TRs and 32P-labeled DR-4.
In vitro receptor synthesis was performed using plasmids
encoding hTRβ 1 hRXRα , and hPPARγ  [38] and hVDR [39]
with the TNT-coupled Reticulocyte Lysate System
(Promega, Madison, WI) containing a methionine-free
aminoacid mixture, and either 20 µM cold methionine or
35S-labeled methionine. DNA plasmid (0.2–2 µg) was
added to TNT Quick Master Mix and incubated in 50 µL
for 90 min at 30°C. To confirm efficiency of the transla-
tion reaction 35S-labeled translated proteins were ana-
lyzed by sodium dodecyl sulfate gel electrophoresis (SDS-Nuclear Receptor 2005, 3:1 http://www.nuclear-receptor.com/content/3/1/1
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PAGE). The TR-DNA complex was visualized by labeling
reticulocyte lysate-translated receptors with 35S or by
using labeled DNA with 32P using polynucleotide kinase.
Prior to incubation with DNA, the reticulocyte lysate-
translated receptors were treated with TRβ 1, VDR and
PPARγ  receptors ligands (T3, 1,25-dihydroxy-vitamin D3;
and 9-cis-retinoic acid respectively) for 30 min at 4°C.
Labeled nuclear receptor plus ligands were then incubated
in different volumes (0.5, 1 and 2 µL) of uremic or normal
plasma for 30 min at 4°C. Following plasma exposure,
the nuclear receptors were incubated for another 20 min
at room temperature (20–30°C) in a solution containing
2 µg non-specific DNA poly (dIdC) (Pharmacia LKB, Pis-
cataway, NJ), cold specific response element (10 ng/reac-
tion), nonradioactive RXRα  and a binding buffer in a 20
µL reaction as previously described [23]. When using non-
labeled nuclear receptors the gel shift experiment was per-
formed using 32P-DR-4 (2000–5000 cpm). A phosphatase
inhibitor cocktail 2 (Sigma, P 5726) was added when the
DNA was labeled (32P-DR-4). The binding buffer con-
tained 0.2 mM Na2HPO4, 0.2 mM NaH2PO4, 1 mM
MgCl2, 0.5 mM EDTA, and 5% glycerol. Final samples
were loaded on 5% nondenaturing polyacrylamide gel,
previously run for 30 min at 200 V. To separate the pro-
tein-DNA complexes, the gel was run at 4°C for 90–180
min at 240 V, using a running buffer (pH 7.5 for 10X stock
at room temperature) containing 6.7 mM Tris-base, 1 mM
EDTA, and 3.3 mM Sodium Acetate. The polyacrylamide
gel was dried at the end of electrophoresis and
autoradiographed.
Cell Culture, Transfections and Reporter Gene Assays
Human promonocyte U937 cells were maintained in cul-
ture as previously described [38]. For transfection assays,
cells were collected by centrifugation and resuspended in
transfection solution (0.5 mL/ 1.5 × 107 cells) containing
PBS, 100 mM calcium and 0.1% dextrose and mixed with
2 µg of human TRβ 1 expression vector, 4 µg of the luci-
ferase (Luc) reporter and 500 ng control β -galactosidase
vector. The reporter plasmid contained a synthetic TR
response element containing two copies of DR-4 cloned
immediately upstream of a minimal thymidine kinase
(tk) promoter (-32/+45) linked to luciferase coding
sequences [38]. The cells were transferred to a cuvette and
electroporated using a Bio-Rad gene pulser at 300 V and
960 µF.
Immediately after electroporation, the cells were trans-
ferred to fresh RPMI-1640 medium treated without or
with normal or uremic ultrafiltrate solution (10 fold
concentrated) collected before or after hemodialysis. Cells
were then plated in 12-well dish and treated in triplicates
with T3 10-7M or ethanol (vehicle). After 24 h, cells were
collected by centrifugation, lysed by the addition of 150
µL 1X lysis buffer (Promega) and assayed for luciferase
(kit from Promega Corp.) and β -galactosidase (kit from
Tropix, Inc., Bedford, MA) activities. All transfection
experiments were performed at least three times.
Statistics
Data were analyzed by Kruskal-Wallis test followed by
Dunn's Multiple Comparison Test when applicable. P <
0.05 was considered statistically significant.
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